Retatrutide remains investigational with no MHRA or EMA marketing authorisation
The science behind GLP-1 GLP-1 injectables mimic the natural hormone glucagon-like peptide-1, which plays a crucial role in regulating appetite, digestion, and blood sugar levels
The glucagon component of retatrutide appears to drive this effect, as glucagon promotes hepatic fat oxidation, essentially telling the liver to burn its own stored fat
Although the SAVOR and EXAMINE studies were delineated to verify cardiovascular safety of two DPP-4i, namely saxagliptin and alogliptin, respectively, both are considered to be the first controlled clinical trials to address the effect of GLP-1 system on CVD
PlexusDx clinical protocols emphasize these lifestyle interventions as foundational rather than supplementary to medication therapy
Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration) which may cause kidney problems